ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 339 filers reported holding ACCELERON PHARMA INC in Q3 2021. The put-call ratio across all filers is 0.38 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $3,512,000 | +8.8% | 20,408 | -20.7% | 0.08% | +14.5% |
| Q2 2021 | $3,229,000 | -6.6% | 25,733 | +0.9% | 0.07% | -1.4% |
| Q1 2021 | $3,457,000 | -38.2% | 25,492 | -41.7% | 0.07% | -44.4% |
| Q4 2020 | $5,596,000 | +17.3% | 43,737 | +3.2% | 0.13% | -8.0% |
| Q3 2020 | $4,769,000 | +17.5% | 42,381 | -0.5% | 0.14% | +17.1% |
| Q2 2020 | $4,059,000 | +1.2% | 42,605 | -4.5% | 0.12% | -20.4% |
| Q1 2020 | $4,010,000 | +62.3% | 44,625 | -4.2% | 0.15% | +145.0% |
| Q4 2019 | $2,471,000 | -35.8% | 46,597 | -52.1% | 0.06% | -36.8% |
| Q3 2019 | $3,846,000 | -19.1% | 97,354 | -15.9% | 0.10% | -15.9% |
| Q2 2019 | $4,756,000 | -56.2% | 115,765 | -50.4% | 0.11% | -12.4% |
| Q1 2019 | $10,866,000 | +1102.0% | 233,340 | +882.0% | 0.13% | +706.2% |
| Q1 2015 | $904,000 | +15.0% | 23,762 | +17.8% | 0.02% | +14.3% |
| Q4 2014 | $786,000 | – | 20,168 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |